Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)

New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis

(2021) Annemieke Bloem et al.   Journal of Clinical Medicine

Resistance in Vancomycin-Resistant Enterococci

(2020) William R. Miller et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections — United States

(2019) Athena P. Kourtis et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program

(2019) Daniel J. Diekema et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

(2018) G. Ralph Corey et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010–2014

(2018) M.A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals

(2018) Shelley S. Magill et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections

(2017) Lucas T Schulz et al.   PHARMACOTHERAPY

The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis

(2016) Tristan T. Timbrook et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014

(2016) Lindsey M. Weiner et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin in vitro potency

(2016) Rodrigo E. Mendes et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study

(2014) G. Ralph Corey et al.   CLINICAL INFECTIOUS DISEASES

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

(2014) G. Ralph Corey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Methicillin-Resistant Staphylococcus aureus Central Line–Associated Bloodstream Infections in US Intensive Care Units, 1997-2007

(2009) Deron C. Burton   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Analysis of Clonality and Antibiotic Resistance among Early Clinical Isolates ofEnterococcus faeciumin the United States

(2009) Jessica R. Galloway‐Peña et al.   JOURNAL OF INFECTIOUS DISEASES